These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
757 related articles for article (PubMed ID: 29432077)
1. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077 [TBL] [Abstract][Full Text] [Related]
2. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Philbrick B; Adamson DC Expert Opin Investig Drugs; 2019 Dec; 28(12):1041-1049. PubMed ID: 31726894 [No Abstract] [Full Text] [Related]
3. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. Gállego Pérez-Larraya J; Garcia-Moure M; Labiano S; Patiño-García A; Dobbs J; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; Puigdelloses M; Laspidea V; Astigarraga I; Lopez-Ibor B; Cruz O; Oscoz Lizarbe M; Hervas-Stubbs S; Alkorta-Aranburu G; Tamayo I; Tavira B; Hernandez-Alcoceba R; Jones C; Dharmadhikari G; Ruiz-Moreno C; Stunnenberg H; Hulleman E; van der Lugt J; Idoate MÁ; Diez-Valle R; Esparragosa Vázquez I; Villalba M; de Andrea C; Núñez-Córdoba JM; Ewald B; Robbins J; Fueyo J; Gomez-Manzano C; Lang FF; Tejada S; Alonso MM N Engl J Med; 2022 Jun; 386(26):2471-2481. PubMed ID: 35767439 [TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316 [TBL] [Abstract][Full Text] [Related]
5. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921 [TBL] [Abstract][Full Text] [Related]
6. The Oncolytic Adenovirus DNX-2401 Has Antitumor Activity in Glioblastoma. Cancer Discov; 2018 Apr; 8(4):382. PubMed ID: 29475886 [TBL] [Abstract][Full Text] [Related]
7. DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. Tejada S; Díez-Valle R; Domínguez PD; Patiño-García A; González-Huarriz M; Fueyo J; Gomez-Manzano C; Idoate MA; Peterkin J; Alonso MM Front Oncol; 2018; 8():61. PubMed ID: 29594041 [TBL] [Abstract][Full Text] [Related]
8. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805 [TBL] [Abstract][Full Text] [Related]
9. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma. de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319 [TBL] [Abstract][Full Text] [Related]
12. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. van Putten EHP; Kleijn A; van Beusechem VW; Noske D; Lamers CHJ; de Goede AL; Idema S; Hoefnagel D; Kloezeman JJ; Fueyo J; Lang FF; Teunissen CE; Vernhout RM; Bakker C; Gerritsen W; Curiel DT; Vulto A; Lamfers MLM; Dirven CMF Clin Cancer Res; 2022 Apr; 28(8):1572-1585. PubMed ID: 35176144 [TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Jiang H; Gomez-Manzano C; Lang FF; Alemany R; Fueyo J Curr Gene Ther; 2009 Oct; 9(5):422-7. PubMed ID: 19860656 [TBL] [Abstract][Full Text] [Related]
15. Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations. Ene CI; Fueyo J; Lang FF Neurosurg Focus; 2021 Feb; 50(2):E6. PubMed ID: 33524949 [TBL] [Abstract][Full Text] [Related]
16. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126 [TBL] [Abstract][Full Text] [Related]
17. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nassiri F; Patil V; Yefet LS; Singh O; Liu J; Dang RMA; Yamaguchi TN; Daras M; Cloughesy TF; Colman H; Kumthekar PU; Chen CC; Aiken R; Groves MD; Ong SS; Ramakrishna R; Vogelbaum MA; Khagi S; Kaley T; Melear JM; Peereboom DM; Rodriguez A; Yankelevich M; Nair SG; Puduvalli VK; Aldape K; Gao A; López-Janeiro Á; de Andrea CE; Alonso MM; Boutros P; Robbins J; Mason WP; Sonabend AM; Stupp R; Fueyo J; Gomez-Manzano C; Lang FF; Zadeh G Nat Med; 2023 Jun; 29(6):1370-1378. PubMed ID: 37188783 [TBL] [Abstract][Full Text] [Related]